Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Expert Opinion on Investigational Drugs|September 18, 2014
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's diseaseAnna R Carta, Tanya SimuniJournal of Integrative Neuroscience|September 22, 2022
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of DepressionEzio Carboni, Anna R CartaNeurotoxicity Research|August 8, 2012
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?Anna R Carta, Augusta PisanuHandbook of Experimental Pharmacology|July 30, 2009
Adenosine A2A receptors and Parkinson's diseaseMicaela Morelli, Anna R Carta, Peter JennerBehavioural Pharmacology|August 31, 2006
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?Anna R Carta, Annalisa Pinna, Micaela MorelliMedical Hypotheses|April 29, 2020
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?Elena Carboni, Anna R Carta, Ezio CarboniMethods in Molecular Biology (Clifton, N.J.)|January 9, 2013
The MPTP/probenecid model of progressive Parkinson's diseaseAnna R Carta, Ezio Carboni, Saturnino SpigaFrontiers in Molecular Neuroscience|May 15, 2018
Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson's Disease?Elzbieta Janda, Laura Boi, Anna R CartaParkinson'S Disease|May 24, 2011
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?Anna R Carta, Augusta Pisanu, Ezio CarboniPageof 6